Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07377721

A Study of HRS-2129 in Patients With Diabetic Peripheral Neuropathic Pain

This study aims to investigate the efficacy and safety of HRS-2129 in Chinese diabetic peripheral neuropathic pain (DPNP) in comparison to placebo.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Diabetic Peripheral Neuropathic Pain

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

China-Japan Friendship Hospital, Beijing, Beijing Municipality, China

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Able and willing to provide a written informed consent.
  • Males or females aged ≥18years of age inclusive.
  • Diagnosis of diabetic peripheral neuropathic pain (DPNP) and diabetic peripheral neuropathy (DPN) pain ≥ 3 months.
  • HbA1c ≤ 9.0% at screening and on a stable antidiabetic medication regimen for at least 30 days prior to screening as far as possible.
  • At Screening, pain scale (Visual Analog Scale, VAS) of ≥ 40 mm and < 90 mm.

Exclusion criteria

  • Subjects with a history of severe allergies.
  • Peripheral neuropathy or pain unrelated to diabetic peripheral neuropathy (DPN) that may confuse the assessment of diabetic peripheral neuropathic pain (DPNP).
  • Subjects with abnormal liver and renal function.
  • Corrected QT Interval (QTc): > 450 ms (male), > 470 ms (female).
  • Failure to response to previous treatment with pregabalin at doses ≥ 300 mg/d or gabapentin at doses ≥ 1200 mg/d for treatment of diabetic peripheral neuropathic pain (DPNP).
  • History of suicidal behavior or attempted suicide.
  • Participated in another clinical study within 3 months prior to screening.

Treatment and study plan

HRS-2129 Tablets

Drug

HRS-2129 tablets.

HRS-2129 Placebo

Drug

HRS-2129 placebo.

pregabalin capsules

Drug

Pregabalin capsules.

Pregabalin Capsules Placebo

Drug

Pregabalin capsules placebo.

Primary outcomes

  1. Compare the change from baseline in Average Daily Pain Score (ADPS) between HRS-2129 and placebo at Week 4.

    Time frame: Baseline and Week 4.

    The mean change in Average Daily Pain Score (ADPS) was measured using a 11-point numeric rating scale (NRS; 0 [no pain] to 10 [worst possible pain]). The rating averaged over a 7-day period and was based on entries in patients' daily pain diaries.

Secondary outcomes

  1. Compare the response rate between HRS-2129 and placebo at Week 4 (Proportion of subjects whose ADPS decreased by ≥ 30% and ≥ 50% from baseline).

    Time frame: Baseline and Week 4.

    Ratio of participants responding to treatment, as measured by Average Daily Pain Score (ADPS) reduction from baseline. The ADPS is used to determine categorical response rates.

  2. Compare the change from baseline in ADPS between HRS-2129 and placebo at Week 1 to 4.

    Time frame: From Week 1 to Week 4.

    The mean change in Average Daily Pain Score (ADPS) was measured using a 11-point numeric rating scale (NRS; 0 [no pain] to 10 [worst possible pain]). The rating averaged over a 7-day period and was based on entries in patients' daily pain diaries.

  3. Compare the change from baseline in Visual Analog Scale (VAS) between HRS-2129 and placebo at Week 4.

    Time frame: Baseline and Week 4.

    VAS, in which the participant rates pain on a 100 mm-long horizontal line, where 0 mm = no pain and 100 mm = worst possible pain.

  4. Compare the change from baseline in Short-Form McGill Pain Questionnaire (SF-MPQ) between HRS-2129 and placebo at Week 4.

    Time frame: Baseline and Week 4.

    Participants rate their pain in three parts of the questionnaire, which are combined into a single pain intensity score: Part 1 - 11 descriptors of pain intensity, and 4 descriptors of emotions, on a scale of 0 (none) to 3 (severe); Part 2 - a Visual Analog Scale (VAS), in which the participant rates pain on a 100 mm-long horizontal line, where 0 mm = no pain and 100 mm = worst possible pain; Part 3 - a Present Pain Intensity index in which the participant rates present pain intensity on a scale of 0 (no pain) to 5 (most intense pain).

  5. Compare the Patient Global Impression of Change (PGIC) between HRS-2129 and placebo at Week 4.

    Time frame: At Week 4.

    Patient Global Impression of Change (PGIC) on a 7-point categorical scale, where 1 = very much improved and 7 = very much worse.

  6. Compare the change from baseline in Average Daily Sleep Interference score (ADSIS) between HRS-2129 and placebo at Week 4.

    Time frame: Baseline and Week 4.

    The sleep interference scores on a scale of 0-10, where 0 = pain did not interfere with sleep to 10 = pain completely interfered with sleep. The weekly ADSIS is based on participants daily sleep interference scores.

  7. Number and severity of serious adverse events (SAEs).

    Time frame: From Week 1 to Week 6.

    To evaluate the safety of HRS-2129 during the trial.

  8. Number and severity of adverse events (AEs).

    Time frame: From Week 1 to Week 6.

    To evaluate the safety of HRS-2129 during the trial.

  9. Population Pharmacokinetics (PopPK) characteristics of HRS-2129 in Chinese patients with diabetic peripheral neuropathic pain - Serum concentration of HRS-2129.

    Time frame: From Day 0 to Day 30.

    Population Pharmacokinetics (PopPK) will be determined by measuring serum concentration of HRS-2129.

Study contacts

Contact information is provided by the study sponsor or research team.

Lei Tang

CONTACT

[email protected]

+86-0518-82342973

Sponsors and collaborators

Lead sponsor

Shandong Suncadia Medicine Co., Ltd.

Industry

Registry information

Official study title

A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo and Pregabalin Capsule Controlled, Phase Ib Study to Evaluate the Efficacy and Safety of HRS-2129 in Chinese Patients With Diabetic Peripheral Neuropathic Pain

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Jan 30, 2026
Registry last updated
Apr 15, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.